Literature DB >> 23242522

A complex endocrine conundrum.

G Bano1, V Siedel, N Beharry, P Wilson, T Cranston, S Hodgson.   

Abstract

We describe a case of recurrent primary hyperparathyroidism, manifested as 3 metachronous parathyroid adenomata, in a 50 year-old woman who also had Hashimoto hypothyroidism, gastric gastrointestinal stromal tumour (GIST), cysts in liver and kidneys, 5 intestinal polyps (one of these a villous adenoma), diverticulitis and telangiectasia of lips. She did not have medullary thyroid carcinoma (MTC). Genetic analysis of the CDC73 gene [for Hyperparathyroidism-jaw tumor (HPT-JT)], MEN1 for Multiple Endocrine Neoplasia Type1, CDKN1B for MEN4, SDHB and SDHD for Paraganglioma/Pheochromocytoma susceptibility, VHL for von Hippel-Lindau Syndrome, BMPR1A and SMAD4 for Juvenile Polyposis Syndrome (JPS) (sequencing and MLPA), karyotype and array CGH (44 K) were all normal. She was found to be homozygous for a synonomous germline variant in exon 14 (p. Ser836Ser) of the RET oncogene. This RET variant is of unclear clinical significance, and has been previously reported both in normal individuals and in individuals with MTC. It is unlikely that homozygosity for the RET variant has been casual in the multiple pathologies that our patient has developed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23242522     DOI: 10.1007/s10689-012-9594-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  7 in total

1.  The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.

Authors:  Débora R Siqueira; Mírian Romitti; Andreia P da Rocha; Lucieli Ceolin; Camila Meotti; Aline Estivalet; Marcia K Puñales; Ana Luiza Maia
Journal:  Endocr Relat Cancer       Date:  2010-10-05       Impact factor: 5.678

2.  Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

Authors:  S M Baumgartner-Parzer; R Lang; L Wagner; G Heinze; B Niederle; K Kaserer; W Waldhäusl; H Vierhapper
Journal:  J Clin Endocrinol Metab       Date:  2005-08-23       Impact factor: 5.958

3.  Mutational analysis of RET proto-oncogene among patients with medullary thyroid carcinoma and 'at risk' carriers from India.

Authors:  Rekha Pai; G Arun Nehru; Prasanna Samuel; M J Paul; Nihal Thomas; Jennifer Anne Premkumar; Julie Hephzibah; Nylla Shanthly; Regi Oommen; Aravindan Nair; M S Seshadri; Simon Rajaratnam
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

4.  Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.

Authors:  Andreas Machens; Karin Frank-Raue; Kerstin Lorenz; Susanne Rondot; Friedhelm Raue; Henning Dralle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-05       Impact factor: 3.478

5.  Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?

Authors:  Andreas Machens; Alf Spitschak; Kerstin Lorenz; Brigitte M Pützer; Henning Dralle
Journal:  Clin Endocrinol (Oxf)       Date:  2011-12       Impact factor: 3.478

6.  Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.

Authors:  A Ruiz; G Antiñolo; R M Fernández; C Eng; I Marcos; S Borrego
Journal:  Clin Endocrinol (Oxf)       Date:  2001-09       Impact factor: 3.478

7.  RET polymorphisms and sporadic medullary thyroid carcinoma in a Portuguese population.

Authors:  Patrícia Costa; Rita Domingues; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

  7 in total
  1 in total

1.  Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Margaret von Mehren
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.